Heron Therapeutics, Inc. (Nasdaq: HRTX) 39.8% HIGHER; announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Companys 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
Stemline Therapeutics (NASDAQ: STML) 13.3% HIGHER; announced top-line results from the lead-in stage of its ongoing SL-401 pivotal trial in blastic plasmacytoid dendritic